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Abstract
Objective: Mechanisms of insulin resistance in polycystic ovary syndrome (PCOS) remain 
ill defined, contributing to sub-optimal therapies. Recognising skeletal muscle plays a key 
role in glucose homeostasis we investigated early insulin signalling, its association with 
aberrant transforming growth factor β (TGFβ)-regulated tissue fibrosis. We also explored 
the impact of aerobic exercise on these molecular pathways.
Methods: A secondary analysis from a cross-sectional study was undertaken in women 
with (n = 30) or without (n = 29) PCOS across lean and overweight BMIs. A subset of 
participants with (n = 8) or without (n = 8) PCOS who were overweight completed 12 
weeks of aerobic exercise training. Muscle was sampled before and 30 min into a 
euglycaemic-hyperinsulinaemic clamp pre and post training.
Results: We found reduced signalling in PCOS of mechanistic target of rapamycin (mTOR). 
Exercise training augmented but did not completely rescue this signalling defect in 
women with PCOS. Genes in the TGFβ signalling network were upregulated in skeletal 
muscle in the overweight women with PCOS but were unresponsive to exercise training 
except for genes encoding LOX, collagen 1 and 3.
Conclusions: We provide new insights into defects in early insulin signalling, tissue fibrosis, 
and hyperandrogenism in PCOS-specific insulin resistance in lean and overweight women. 
PCOS-specific insulin signalling defects were isolated to mTOR, while gene expression 
implicated TGFβ ligand regulating a fibrosis in the PCOS-obesity synergy in insulin 
resistance and altered responses to exercise. Interestingly, there was little evidence for 
hyperandrogenism as a mechanism for insulin resistance.
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Introduction
Polycystic ovary syndrome (PCOS) affects 8–13% of 
women of reproductive age (1) has major metabolic 
(increased type 2 diabetes mellitus (T2D) and 
cardiovascular risk factors) (2, 3, 4), reproductive (leading 
cause of anovulatory infertility) (5, 6) and psychological 
(anxiety and depression) (7) impacts, representing a 
substantial health burden. Despite its high prevalence, 
the aetiology and ideal therapies for PCOS remain 
unclear (8). Insulin resistance is a central characteristic 
(9, 10), driving both hyperandrogenism and clinical 
features. The risk of T2D in PCOS is increased 4.4-fold 
independent of BMI (3, 4, 11) accounting for 23% of T2D 
in young women (12); yet, the underlying mechanisms 
of insulin resistance in PCOS remain ill defined (8, 
13). Therapeutic strategies in PCOS include medical 
therapy (metformin) and weight management via diet 
and exercise (6, 14, 15), which reduce but not reverse 
insulin resistance and fail to optimally treat PCOS. In 
this context, greater insight into aetiology of insulin 
resistance in PCOS is needed.
Based on euglycaemic-hyperinsulinaemic clamp 
data, prevalence of insulin resistance has been reported 
in up to 95% of women with PCOS as diagnosed by 
Rotterdam criteria (9). PCOS has a unique PCOS-
related insulin resistance (intrinsic insulin resistance) 
as 75% of lean PCOS are insulin resistant, compared to 
lean women without PCOS. This insulin resistance is 
exacerbated by obesity (extrinsic insulin resistance (9, 
10, 13)). Intrinsic insulin resistance in PCOS is likely due 
to a dysfunctional response to insulin in metabolically 
active peripheral tissues including adipose tissue and 
skeletal muscle (8, 13). As skeletal muscle accounts for 
70–80% of insulin-stimulated glucose uptake (16) defects 
may have profound effects on whole body insulin 
sensitivity. Reduced insulin sensitivity in skeletal muscle 
has well-established mechanisms including defective 
insulin signalling (17, 18), with reduced activation of 
key signalling proteins such as insulin receptor substrate 
(IRS)1/2, protein kinase B (PKB)/Akt and its downstream 
substrate Akt substrate 160KDa (AS160) (17, 18, 19). 
While similar defects in insulin stimulated signalling 
have been found in women with PCOS (13, 20), these 
signalling defects are not consistent (21) and unable to 
explain the PCOS-specific IR.
Raja-Khan et  al. (22) has proposed an alternative 
hypothesis that dysfunctional transforming growth 
factor β (TGFβ) signalling regulated by fibrillins and 
latent TGFβ-binding proteins may lead to increased 
organ stroma or fibrosis. This may predispose women 
with PCOS to morbidities like insulin resistance, as TGFβ 
can directly impact glucose uptake and insulin signalling 
(23, 24, 25) and/or create a physical barrier to glucose 
uptake into muscle (26). The role of aberrant extracellular 
matrix (ECM) remodelling or tissue fibrosis and TGFβ in 
the aetiology of PCOS-related insulin resistance has not 
been investigated.
We therefore hypothesised that the women with PCOS 
compared to BMI-matched controls would be associated 
with unique defects in insulin signal transduction and 
altered ECM and TGFβ signalling network gene expression. 
We aimed to examine the activation/phosphorylation 
of proteins in both the proximal and distal parts of 
the insulin signalling cascade before and 30 min into 
a euglycaemic–hyperinsulinaemic insulin clamp and 
gene expression of the ECM and TGFβ ligand signalling 
network in women with or without PCOS (spanning lean 
and obese BMIs). Our secondary aim was to investigate 
the impact of exercise training on the aberrant skeletal 
muscle insulin signalling and gene expression of the ECM 
and TGFβ ligand signalling network.
Materials and methods
Participants
The participants that are included in this secondary 
analysis are a subset of women who participated in 
our previously published studies (9, 27, 28, 29) and 
consented to muscle biopsies. Specifically, we included 
fifty-nine (Fig. 1 and Table 1) of the original cohort of 
premenopausal women with or without PCOS. The 
women were categorised according to PCOS status and 
matched (group means) for BMI generating four groups: 
(i) lean with PCOS (LP), (ii) lean without (control; LC), 
(iii) overweight to obese with PCOS (OWP) and (iv) 
overweight to obese without PCOS (control; OWC). 
Confirmation of PCOS diagnosis was undertaken by 
expert endocrinologists (SKH, AEJ and HJT) based on 
Rotterdam criteria. The Southern Health Research 
Advisory and Ethics Committee approved the study and 
participants gave written informed consent. The clinical 
trial registration number is ISRCTN84763265.
Study design
For this ancillary mechanistic observational study and 
interventional sub-study (Fig. 1) data were collected 
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at baseline in all women (after three-month washout 
of relevant medications) and following 12 weeks of 
exercise training (subgroup of women with overweight/
obesity n = 8 per group). Data were collected in the 
follicular phase of the menstrual cycle in control women 
and wherever feasible in the women with PCOS. End-
point analyses were done by staff blinded to group and 
intervention stage.
Exercise intervention
The subgroup of overweight to obese participants 
consisting of women with PCOS (n = 8) and without 
PCOS (controls; n = 8) undertook 12 weeks of supervised, 
personalised progressive, aerobic exercise training on 
a motorised treadmill as described previously. Briefly, 
participants attended three 1 h sessions each week, which 
sequentially alternated between moderate-intensity 
(walking or jogging at 70% of VO2peak or 75–85% HRmax) 
and high-intensity interval training (six 5-min intervals 
with 2-min recovery period at approximately 95–100% 
of VO2peak or approximately 95–100% HRmax). The 
intensity and/or duration of each participant’s exercise 
session were individually progressed and increased over 
the duration of the intervention (28, 29, 30).
Clinical and biochemical measurements
Participants were assessed for anthropometric measures 
including body weight, height, body composition, 
abdominal visceral fat and subcutaneous fat and, waist, 
and hip circumference as Table 1. Insulin sensitivity was 
determined using the euglycaemic-hyperinsulinaemic 
clamp technique (40 mU/m2/min) as previously reported 
(9). Blood samples were batch analysed for fasting 
glucose, total cholesterol, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, 
triglycerides, insulin, testosterone and HbA1c. Low-
density lipoprotein and the homeostatic model insulin 
resistance assessment (HOMA) were calculated (31).
Thigh muscle (vastus lateralis) samples were 
obtained by percutaneous biopsy under local 
anaesthesia (29) immediately prior to and 30 min into 
the insulin clamp. Muscle biopsies were immediately 
frozen in liquid nitrogen and then stored at −80°C for 
subsequent analysis.
Figure 1
Consort flow diagram detailing the sample size 
and prior research studies for the secondary 
analysis reported in the current study.
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Muscle protein extraction and Western 
blot analyses
Equal quantities of protein, extracted as previously 
reported (32, 33, 34), were resolved by SDS-PAGE (Bio-Rad, 
Criterion TGX Gels), transferred to a PVDF membranes 
(Bio-Rad, Turbo-Blot) using optimised protocols, blocked 
with TBST (10 mM Tris; 10% Tween 20) containing 
5% skim milk, washed 4 times for 5 mins in TBST and 
immunoblotted overnight at 4°C with primary antibodies 
(32, 33, 34) targeting total and phospho-proteins 
including glucose transporter 4 (GLUT4), insulin receptor 
(IR), insulin receptor substrate 1 (IRS-1), protein kinase 
B/Akt, Akt substrate 160 kDA (AS160), typical and atypical 
phospho-protein kinase C (PKCδ/θ; PKCλ/ζ), mechanistic 
target of rapamycin (mTOR), glycogen synthase kinase 
3α (GSK) and glyceraldehyde phosphate dehydrogenase 
(GAPDH) as the loading control (Supplementary Table 1, 
see section on supplementary materials given at the end of 
this article). After washing and incubation with horseradish 
peroxidase-conjugated secondary antibody (Perkin Elmer) 
in 5% skim milk and TBST, the immune-reactive proteins 
were detected with enhanced chemiluminescence 
(Amersham Biosciences) on the Versadoc MP4000 (Bio-
Rad) and quantified by densitometry (Quantity-One; Bio-
Rad). All phospho-protein data were normalised to their 
total protein, unless otherwise indicated (Figs 2, 4 and 
Supplementary Figs 1, 2) to control for loading variability.
RNA extraction and TGFβ network/tissue fibrosis 
gene expression analysis
Total RNA was isolated from the muscle (15–20 mg) 
using TRIzol and cleaned up with RNeasy Total RNA Kit 
columns (Qiagen). The total RNA content and purity were 
established by measuring absorbance at 260 and 280 nm 
(NanoDrop; Eppendorf). Ten micrograms of each RNA 
sample were then DNAse treated using DNase 1 (Thermo 
Fisher Scientific) described in detail in (35).
Relative gene expression was quantified by real-
time PCR using the Qiagen RT2 custom profiler array for 
fibrosis pathway-related genes. 100 ng of DNAse-treated 
RNA was used for cDNA, diluted 1 in 10 and amplified for 
14 genes plus 2 housekeeping genes. cDNA was generated 
according to manufacturer’s guidelines with modifications 
(35) using 40 µL of Superscript RT III (Thermo Fisher 
Scientific). Custom array primers were designed against 
the human mRNA sequences for the corresponding genes 
in the Ref Seq database (Supplementary Table 2).
All reactions were performed according to the Sybr-
Green™ cycle threshold (Ct) method using a Biorad CFX 
384 real-time PCR detection. Thermocycling conditions 
for the PCR included 10 min at 95°C followed by 40 cycles 
of 15 s at 95°C and 1 min at 60°C. Melt curve analysis from 
72 to 95°C (5 s per °C) was performed to ensure a single 
defined peak for each amplified product. Comparative Ct 
calculations for the gene expression were performed by 
subtracting the mean GAPDH and ACTB Ct values from 
Ct values of the gene of interest to derive a ΔCt value. The 
expression of the genes was calculated according to the 
formula: 2−ΔCt.
Statistical analysis
All statistical analyses were conducted using mixed 
modelling procedures (PROC MIXED) in Statistical 
Analysis System (version 9.4, SAS Institute). Data, unless 
otherwise stated, were log transformed before analysis 
to overcome heteroscedastic issues and presented as a 
back-transformed mean with standard deviation (s.d.) as 
a coefficient of variation (CV; %). For the cross-sectional 
study separate models were generated to compare 
differences in variables between groups including 
participant characteristics, gene expression, where the 
fixed effects in the model estimated the main effects 
of PCOS (PCOS/Control) and obesity (BMI - Lean (<27 
kg/m2) and overweight (>27 kg/m2) as per (9)) status 
as nominal variables and the modifying effect of age 
a linear numeric variable. To estimate the main effects 
of PCOS and BMI on the fold change (with an s.d. as 
expressed CV %) in normalised protein phosphorylation 
induced by 30 min of insulin infusion the fixed effects 
were again PCOS and BMI status as nominal variables 
interacted with baseline phosphorylation levels, age 
and change plasma insulin concentrations (linear 
numeric variables). For the exercise training sub-
study, a similar approach was adopted and the main 
effects of PCOS (PCOS/Control) and training status 
(untrained vs trained) on participant characteristics, 
gene expression, baseline protein abundance and 
insulin-induced changes phospho-protein abundance 
were determined with the fixed effects in the model 
where PCOS and training status as nominal variables 
and interacted with the dependent variables baseline 
value. All models estimated between group differences 
of variables or changes in variables as a percentage and 
presented with 99% confidence intervals (99% CI). 
Pearson correlations (PROC CORR; SAS v9.4) were used 
explore relations between GIR and a select number of 
variables. Significance was accepted when P < 0.05. As an 
a priori decision, we ran a parallel analysis on our mixed 
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model outcomes using a Bayesian method that has no 
or minimally informed prior or belief about the effects 
or standard deviations or magnitude-based inferences 
(10, 36). This method allowed us to make probabilistic 
assertions about the true magnitudes of effects using 
the non-clinical version of magnitude-based inference, 
according to which an effect was deemed unclear if the 
99% CI spanned substantial positive and negative values 
of the smallest worthwhile effect (0.2 times between 
participant s.d.); all other effects were deemed clear and 
assigned the magnitude of the analysed effect, along 
with the chances that the effect was substantial and/or 
trivial (36). The magnitude-based inference component 
of our combined statistical approach was used to 
provide a standardised effect size (<0.2, trivial; 0.2–0.6, 
small; 0.6–1.2 moderate, 1.2–2 large) and to account 
for inflation of error arising from the large number 
comparisons investigated. We only reported effects 
that met our significance criteria (P < 0.05) and were 
deemed to have a clear standardised-effect by 
magnitude-based inference for the 99% CI of the 
analysed effect.
Results
All clinical data differentiating the different groups 
of women from the subset of participants used in this 
analysis and the beneficial impact of exercise training 
are detailed in Table 1. Between-group differences for 
insulin-stimulated phosphorylation signalling protein 
abundance and gene expression are reported as fold 
changes with 99% CI that includes the adjustments for the 
appropriate covariates.
Insulin signalling
Abundance of key phospho-proteins in the insulin 
signalling pathway across the distal and proximal 
components, as well as the insulin signalling pathway 
regulators were analysed across the four groups of 
women to identify early insulin signalling defects in 
skeletal muscle that align with PCOS-specific insulin 
resistance (Fig. 2 and Supplementary Fig. 1). Overall 
30 min of insulin infusion stimulated phosphorylation 
of the signalling proteins across all groups where 
Figure 2
Normalised fold change of insulin stimulated (30 min) phosphorylation of key proteins in the insulin signalling pathway and insulin signalling pathway 
regulators. (A) insulin receptor (IR), (B) insulin receptor substrate 1 serine 307 (IRS1), (C) protein kinase B/Akt serine 473 (Akt), (D) Akt threonine 308, (E) 
atypical protein kinase B (PKC (ζ/λ)), (F) typical PKC (δ/θ), (G) mechanistic target of rapamysin (mTOR), (H) Akt substrate 160 kDa (AS160), (I) glycogen 
synthase kinase ser 21/9. Covariate adjusted statistical difference reported as: *significant fold increase with insulin stimulation P < 0.05 (and clear effect 
at 99%CL), **significant fold increase with insulin stimulation P < 0.01 (and clear effect at 99%CL), Psignificant impact of PCOS P < 0.05 (and clear effect at 
99%CL), Osignificant impact of obesity P < 0.05 (and clear effect at 99%CL). Presented as mean ± s.d. (data presented as back transformed and the s.d. was 
derived as a coefficient of variation (%)), P < 0.05.
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IR-tyr1162/1163, Akt-ser473, Akt-thr308, mTOR, AS160-thr642  
and GSK-ser21/9 underwent significant/meaningful increases 
(P < 0.05 and large effects) ranging from 1.6 to 4.4-fold 
(Fig. 2). Only one signalling protein, mTOR demonstrated 
altered phosphorylation, after adjustments for covariates, 
where obesity and PCOS reduced phosphorylation. 
Specifically, PCOS resulted in a moderate 0.6 fold ((99% CI 
0.4–0.8), P = 0.01) reduction of phosho-mTOR compared 
to non-PCOS women. Similarly, obesity also induced a 
moderate 0.6 fold ((99% CI 0.4–0.9) P = 0.019) compared 
to lean women. Taken together these data suggest 
altered insulin-sensitive metabolic signalling distal to 
Akt which may impact the translocation of the glucose 
transporter protein GLUT4 and therefore glucose uptake 
into muscles. We found no differences in protein expression 
of GLUT 4 between the groups (data not shown).
Gene expression for tissue fibrosis
The relative gene expression of COL1A2, COL3A1, DCN, 
IGF1, LOX, LTBP1, TGFB2 and TGFBR2 was impacted by 
both obesity and/or PCOS status with small to moderate 
between-group differences (Fig. 3) suggesting aberrant 
signalling via the TGFβ ligand signalling network, 
establishing a pro-fibrotic gene program. Specifically, 
COL1A2 and 3A1 were 2.14 fold (99% CI: 1.8, 2.4; 
P = 0.001) and 2.12 fold (99% CI: 1.7, 2.4%; P = 0.005) 
higher in OWP compared to OWC. The OWC group had 
higher (1.83 fold; P < 0.05) expression of both COL1A2 
and 3A1 compared to LC. The LTBP1 gene expression 
was highest in the overweight groups, with OWP having 
significantly higher (0.75 fold, 99% CI: 0.6, 0.9; P = 0.008) 
expression than LC. For DCN (1.94 fold, 99% CI: 1.5, 2.2; 
P = 0.005) and LOX (2.44 fold 99% CI: 1.7, 2.7; P = 0.021) 
the OWP group had higher gene expression than OWC. 
While DCN in LC was lower (0.66 fold, P = 0.031) and LOX 
was 2.98 fold higher (P = 0.025) than OWC. The TGFβ 
signalling-related gene expression was higher in the OWP 
group where TGFB2 and TGFBR2 expression were 1.8 fold 
(99% CI: 1.5, 2.0; P = 0.0009) and 1.76 fold (99% CI: 1.4, 
2.0, P = 0.004) higher in OWP compared to LC respectively. 
TGFBR2 gene expression was 1.8 fold higher in OWP vs 
OWC (P = 0.005). In contrast, IGF1 gene expression was 
lowest in OWC being 2.5 fold (99% CI: 1.6, 4.1; P = 0.006) 
compared to LC, with OWC also being lower (0.48 fold 
99% CI: 0.3, 0.8; P = 0.026) than OWP.
Overall GIR negatively correlated with body 
composition (BMI; android, gynoid and visceral fat; 
and DXA-derived fat free mass and appendicular muscle 
mass) and FAI (Supplementary Table 3). In contrast, GIR 
was positively correlated with aerobic fitness and SHBG 
concentrations (Supplementary Table 3). These overall 
associations were due to the stronger correlations observed 
in the women with PCOS compared to controls across 
the BMI categories. GIR was also positively correlated to 
the fold change in insulin-stimulated (30 min) phospho-
mTOR (r2 = 0.43, P = 0.02) in the PCOS group only and 
negatively correlated to TGFBR2 gene expression overall 
(r2 = −0.37, P = 0.03).
Impact of exercise
In the women (with overweight/obesity) who participated 
in the 12-week treadmill exercise intervention a number 
of changes in clinical features (Table 1), insulin signalling 
(Fig. 4 and Supplementary Fig. 2) and TGFβ signalling 
network gene expression (Fig. 5) were observed. Training-
induced differential responses to 30 min of insulin 
stimulation, where only phospho-Aktser473 and phospho-
GSKser219 were impacted differently by the training 
intervention. OWP demonstrated a small attenuation 
in phosphorylation of phospho-Aktser473 (0.45 fold 
99% CI: 0.3, 0.8; P = 0.019) and phospho-GSKser219  
(0.48 fold 99% CI: 03, 0.8; P = 0.027) compared to OWC 
women, respectively. Surprisingly, very few phospho-
proteins demonstrated clear with-in group impacts 
of training. Specifically, training resulted in a large 
augmentation of insulin-stimulated phospho-AS160 of 1.82 
fold (99% CI: 1.2, 2.7; P = 0.025) from pre- to post-training 
in OWP. On the other hand, training resulted in a small 
attenuation of phospho-GSKser219 (0.58 fold 99% CI: 
0.4, 07; P = 0.006) from pre- to post-training in OWP group.
We also reported small to moderate differential 
training-induced changes in relative gene expression 
(Fig. 5) of genes for ECM deposition, COL1A2, COL3A1, 
DCN and LOX, which only occurred in OWP women. 
COL1A2 gene expression increased by 1.65 fold (99% CI: 
1.2, 2.2; P = 0.02) from pre- to post-training in the OWP 
women. Similarly exercise training induced COL3A1 and 
LOX gene expression increases of 1.94 fold (99% CI: 1.1, 
3.4; P = 0.05) and 1.95 fold (99% CI: 1.3, 3.0; P = 0.03), 
respectively.
The exercise-induced changes in GIR did not correlate 
with any fold changes in insulin-induced increases/
decreases in protein phosphorylation nor changes in 
gene expression (Supplementary Table 4) in any group. 
However, changes in FAI were negatively correlated with 
the training-induced changes in GIR (r2 = −0.74; P = 0.04) 
in women with PCOS, indicating increased insulin 
sensitivity was associated with a decreased FAI.
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Figure 3
Relative gene expression of the tissue fibrosis 
(TGFβ) pathway. Gene expression was normalised 
to the mean of GAPDH and ACTB (the 
housekeeping genes) expression. (A) COL1A2, (B) 
COL3A1, (C) DCN, (D) IGF1, (E) LOX, (F) SMAD2, (G) 
TGF1I1, (H) LTBP1, (I) TGFB1, (J) TGFB2, (K) TGFB3, (L) 
TGFBR2. These data are from a subset of women 
(n = 59) (9). Covariate adjusted statistical 
difference reported: a- significantly different from 
overweight control P < 0.05 (and clear effect at 
99%CL), b- significantly different from overweight 
PCOS P < 0.05 (and clear effect at 99%CL). Data 
are presented as mean ± s.d. (data presented as 
back transformed and the s.d. was derived as a 
coefficient of variation (%)).
Figure 4
Normalised fold change of insulin stimulated (30 min) phosphorylation of key proteins in the insulin signalling pathway before and after 12 weeks of 
intensified aerobic exercise training in overweight women with and with PCOS. (A) insulin receptor (IR), (B) insulin receptor substrate 1 serine 307 (IRS1), 
(C) protein kinase B/Akt serine 473 (Akt), (D) Akt threonine 308, (E) atypical protein kinase B (PKC (ζ/λ)), (F) typical PKC (δ/θ), (G) mechanistic target of 
rapamysin (mTOR), (H) Akt substrate 160 kDa (AS160), (I) glycogen synthase kinase ser 21/9. These data are from a subset of women (n = 8 PCOS, n = 8 
control) from (28, 29). Covariate adjusted statistical difference reported as: *significant fold increase with insulin stimulation P < 0.05 (and clear effect at 
99%CL), **significant fold increase with insulin stimulation P < 0.01 (and clear effect at 99%CL), asignificantly different between group training response 
P < 0.05 (and clear effect at 99%CL), bsignificantly with in group training response P < 0.05 (and clear effect at 99%CL). Presented as mean ± s.d. (data 
presented as back transformed and the s.d. was derived as a coefficient of variation (%)).
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Discussion
Taking a novel sampling approach, this study 
demonstrated dysfunction in insulin signalling after 30 
min of insulin infusion during an insulin clamp in women 
with PCOS across a range of BMIs. This dysfunction was 
distal to Akt/PKB and associated with end-clamp insulin 
sensitivity. Specifically, reduced insulin stimulated 
phospho-mTOR was associated with PCOS and obesity 
status. A 12-week exercise intervention improved, but did 
not rescue insulin sensitivity in OWP compared to OWC 
women and these improvements were accompanied 
by augmented phospho-AS160 and phospho-mTOR 
(trend) but attenuated phospho-Akt-ser473 and phosho-
GSKser21/9in PCOS. We found genes in the TGFβ regulated 
tissue fibrosis pathway that encode ECM components 
(COL1A2, COL3A1), enzymes in the collagen deposition 
and assembly (LOX, DCN), ligands (TGFB2) and their 
receptor were elevated in OWP. After the 12-week training 
intervention COL1A2, COL3A1, DCN and LOX were 
differentially regulated in the OWP compared to OWC 
women. Overall women with PCOS, especially the OWP 
showed a gene expression pattern conducive to greater 
TGFβ ligand-driven ECM or fibrosis, even after the exercise 
training intervention.
Defects in insulin signalling in skeletal muscle are 
well documented for insulin-resistant conditions (17), 
including PCOS (13, 37). Our data significantly expands 
this work exploring possible defects in both proximal and 
distal components of this pathway in lean and overweight 
controls and women with PCOS. In agreement with 
the literature (13, 17, 37) our data demonstrated an 
obesity-induced defect in the insulin receptor activation 
of signalling, due to differential phosphorylation of 
tyr1162/1163 between the lean and overweight groups with 
no impact of PCOS status. When obesity (BMI) and 
prevailing insulin concentrations were accounted for, the 
obesity-driven differences were negated and the lack of 
impact of PCOS status remained (Fig. 2), as previously 
reported (13, 37). Our data allowed us to explore the 
hypothesis of Diamanti-Kandarakis and Dunaif (13) 
where there may be a PCOS-specific serine kinase targeting 
IRS1/2. mTOR could be this kinase (38, 39), however, our 
in vivo data contrast with this hypothesis as no insulin-
stimulated change was detected in any group. These data 
suggest that signalling defects are more likely distal to the 
IR and IRS1/2 in skeletal muscle of women with PCOS.
A key finding of this study, was that our in vivo 
data show reduced phosphorylation of mTOR occurred 
in PCOS-specific manner and implicates this protein 
Figure 5
Training response of relative gene expression in 
the tissue fibrosis (TGFβ) pathway for women with 
and without PCOS after 12 weeks of intensified 
exercise training. (A) COL1A2, (B) COL3A1, (C) DCN, 
(D) IGF1, (E) LOX, (F) SMAD2, (G) TGF1I1, (H) LTBP1, 
(I) TGFB1, (J) TGFB2, (K) TGFB3, (L) TGFBR2. These 
data are from a subset of women (n = 8 PCOS, 
n = 8 control) from (28, 29). Presented as 
mean ± s.d. (data presented as back transformed 
and the s.d. was derived as a coefficient of 
variation (%)). Covariate adjusted statistical 
difference reported: *significant within group 
training effect P < 0.05 (and clear effect at 99%CL), 
asignificant difference between OWC and OWP 
P < 0.05 (and clear effect at 99%CL).
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complex as a mechanism of insulin resistance in PCOS 
(Supplementary Table 3). These data differ from a recent 
study (21) investigating insulin signalling defects in 
lean hyperandrogenic women with PCOS, where defects 
in adenosine monophosphate kinase (AMPK) and 
pyruvate dehydrogenase (PDH) activity explain insulin 
resistance. This work was not without limitations (e.g. 
lean women only, no fitness assessments (8)) and did 
not consider mTOR, the alternate metabolic signalling 
pathway. mTOR signalling via its complex mTORC1 
(mTOR + raptor) is associated with nutrition-regulated 
anabolic processes in skeletal muscle (40). More recently 
the mTORC2 (mTOR+rictor) has been linked to insulin 
resistance in skeletal muscle in vitro and animal models 
in the presence of reduced phospho-Akt ser473, altered 
intracellular glucose handling, irrespective of levels of 
phospho-Akt-thr308 and GLUT4 vesical trafficking (39). 
The women with PCOS from the exercise training sub-
group had improved, but not rescued mTOR signalling 
responses to insulin, which did not correlate with 
training-induced changes in GIR (Supplementary Table 
4). As we were unable to quantify the different mTOR 
complexes, due to tissue availability, we could not 
establish if mTORC2 was associated with this PCOS-
specific reduction in insulin signalling and sensitivity. 
More research is needed to understand the PCOS-specific 
mTOR downregulation and its role in the intrinsic 
insulin resistance in skeletal muscle.
AS160, GSK3, typical PKC (δ/θ) and atypical PKC (λ/ξ) 
insulin-stimulated phosphorylation were surprisingly 
similar between groups but there were trends for obesity 
to reduce signalling. GLUT4 is considered important in 
skeletal muscle insulin and exercise stimulated glucose 
uptake (26) where our data for protein expression of 
GLUT4 (data not shown) surprisingly found no differences 
between the four groups of women. While these data 
align with previous work suggesting comparable levels 
of GLUT4 between women with and without PCOS (41), 
our methodology (centrifuged muscle lysate and heating 
prior to gel separation) may mask/underestimate any true 
differences and effects. The 12-week exercise intervention 
clearly impacted the dysfunctional phosphorylation of 
three signalling proteins. Specifically, phospho-AS160, 
a key protein in Glut4 vesicle translocation (42), was 
improved in the OWP women, aligning with other training 
studies (in males (32)). On the other hand phospho-
Akt and –GSK3 (regulation of glycogen synthesis (38)) 
demonstrated contradictory reductions post-training in 
the OWP women. This was unexpected, especially the 
reduced phospho-Akt; however, there is the non-linearity 
of signalling via Akt (43) and thus limiting its impact on 
any training induced improvements of GIR in OWP. The 
training intervention did not induce significant changes 
in the other signalling proteins, each having a vital role 
in regulating insulin-stimulated glucose uptake either as 
downstream substrates of Akt or independently including 
regulation of Glut4 vesicle translocation (Atypical PKC 
(λ/ξ) (44)) and integration lipid availability to reduce 
glucose uptake (typical PKC (δ/θ) (45, 46)). In summary, 
our data suggest that the reduced early activation 
of proteins below Akt are linked to PCOS–specific 
insulin resistance. This is despite the alteration but not 
normalisation of phosphorylation defects by training. 
Overall, these data and that of others (9, 10) suggests 
insulin signalling defects in skeletal muscle account 
for some insulin resistance, but additional molecular 
mechanisms are responsible for the PCOS-specific insulin 
resistance and its synergy with obesity.
There is emerging data suggesting that at least TGFβ2 
is an exercise induced adipokine that promotes insulin 
sensitivity (25). However, these data are currently biased 
to male samples and mainly rodent physiology but they 
do further support the notion that TGFβ pathways are 
important for insulin sensitivity and response to exercise. 
Human data supporting (23, 24) induction of insulin 
resistance provide a direct role of TGFβ signalling, via the 
SMAD proteins in skeletal muscle glucose uptake. In the 
context of the aetiology of PCOS, our new hypothesis 
(22) of TGFβ ligand mediated excess stromal deposition 
or fibrosis, may apply beyond the ovary to metabolic 
tissues like skeletal muscle in women with PCOS, 
predisposing them to insulin resistance. Dysfunctional 
TGFβ or TGFβ superfamily ligand signalling may be 
involved as anti-müllerian hormone (AMH) (47) and 
TGFβ1 (48) are elevated in women with PCOS. These 
ligands act via their respective receptors to activate the 
SMAD signalling proteins that are not only negative 
regulators of Akt (49) and mTOR (24), but are key signals 
in ECM deposition. Thus, this pathway is a plausible 
contributor to dysfunctional insulin signalling and 
reduced sensitivity in PCOS. Our gene expression data of 
elevated collagen, ECM deposition enzymes and TGFβ2R 
gene expression (pro-fibrotic gene profile), elevated 
ligands (AMH (47) and TGFβ1 (48)) and our previously 
reported high tissue density (elevated Hounsfield 
units) in thigh skeletal muscle from CT analysis (29), 
support the notion that TGFβ ligand signalling and 
tissue fibrosis may be involved in PCOS-specific skeletal 
muscle insulin resistance (8). This may occur not 
only via SMAD protein signalling interfering with Akt 
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and/or mTOR signalling, but also via increased ECM 
possibly limiting insulin and glucose movement across 
the interstitial space. Interestingly, exercise training had 
no effect on this network of genes except LOX, COL1A2 
and 3A1 where expression was augmented. This provides 
a possible mechanism for resistance to insulin sensitising 
therapies in PCOS, which aligns with other research (23) 
and warrants further investigation. Therefore, our data 
support our hypothesis (22) and allows us to expand 
our understanding of insulin resistance in skeletal 
muscle in PCOS and its attenuated response to therapy. 
We now propose that the TGFβ ligand signalling via 
SMAD-mTOR/SMAD-Akt pathways plus tissue fibrosis 
is mechanistically involved in PCOS-specific insulin 
resistance, its synergy with obesity (Fig. 6) and possible 
resistance to therapy.
Our study limitations included a small sample 
size (9, 28, 29) due to the invasive procedures used to 
obtain tissue samples. As this was an ancillary analysis 
tissue availability was limited (additional analysis via 
immunoblotting of TGFβ signalling) and not collected 
to for immunohistochemistry. We acknowledge that 
the sample size was limited for the exercise arm of the 
study, which may have limited power to detect exercise-
induced alterations in fibrosis in the OWC group. 
Alternatively, we could also speculate that perhaps on 
OWC exercise does not re-model the ECM unlike the 
OWP. However, the strengths of this work were the use 
of gold-standard methods to assess insulin sensitivity in 
a community-recruited, well-characterised population 
of lean and overweight women with or without PCOS. 
We cannot rule out contributions of differential body 
composition and other systemic factors (Supplementary 
Tables 3 and 4) to insulin resistance in women with 
PCOS. Specifically, FAI index correlated strongly 
(negatively) with end clamp GIR in women with PCOS 
but not controls, but were no longer significant when 
LP and OWP were considered separately (r2 ~ −0.40, 
P > 0.05). Additionally, exercise-induced reduction in 
FAI correlated strongly with the increases in GIR for the 
sub-group of PCOS women. These data suggest a role 
of hyperandrogenism in PCOS-specific IR. However, FAI 
did not correlate with any insulin signalling or TGFβ and 
tissue fibrosis gene expression data in this study. FAI is a 
calculated variable dependant on SHBG concentrations, 
which are impacted by insulin resistance (50). Taken 
together with most literature (10, 13) this study could 
not establish the role of hyperandrogenism in causing 
insulin resistance in PCOS via peripheral tissue insulin 
signalling and fibrosis.
Conclusions
Our data provide new insights into PCOS-specific insulin 
resistance and the associated early signalling events in 
skeletal muscle highlighting a role for aberrant mTOR 
signalling. These data also support our hypothesis that 
TGFβ superfamily ligands, their signalling and tissue 
fibrosis are involved in PCOS-specific insulin resistance, 
Figure 6
Hypothetical signalling pathway showing that 
dysfunctional TGFβ network signalling regulates 
tissue fibrosis and may play a role in this 
PCOS-specific insulin resistance and its limited 
response to exercise training.
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particularly driving the synergy between obesity and 
PCOS. Intensified aerobic exercise training did not restore 
insulin sensitivity, despite improving insulin stimulated 
signalling at Akt, AS160 and mTOR in overweight women 
with PCOS. There was no clear evidence to support a role for 
hyperandrogenism in peripheral tissue insulin resistance, 
in women with PCOS. Overall, additional human research 
(in vivo and in vitro), supported by appropriate animals 
studies, is warranted to elucidate the role of androgens, 
mTOR signalling, TGFβ ligand signalling networks and 
ECM deposition in PCOS-specific insulin resistance.
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